Pancreatic Cancer Research

ResearcherIstanbul UniversityActive in the last 2 years

Senem Karabulut

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4740-9973; OpenAlex author ID A5088008421. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 12

  1. Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer? Co-author DOI 10.25259/cytojournal_2_2025↗
  2. A Pilot Study of Exploring miRNA-Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis. Co-author DOI 10.3390/diagnostics15192479↗
  3. Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma? Co-author DOI 10.4103/jcrt.jcrt_469_23↗
  4. Circulating annexin A2 as a biomarker in patients with pancreatic cancer. Last author DOI 10.4103/jcrt.jcrt_755_18↗
  5. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Co-author DOI 10.3390/biom8040169↗
  6. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jiac.2016.12.003↗
  7. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s12029-015-9787-z↗
  8. Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.bbacli.2016.10.002↗
  9. Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy. Co-author PMID 27685911↗
  10. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. First author DOI 10.1007/s00280-014-2450-8↗
  11. Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma. First author DOI 10.1007/s12029-013-9512-8↗
  12. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. First author DOI 10.1007/s13277-013-0931-8↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Çiğdem Usul Afşar · 6 shared papers, 2016–2024 · strength 0.60
  2. Didem Taştekin · 3 shared papers, 2013–2025 · strength 0.60
  3. Sena Şen · 2 shared papers, 2025 · strength 0.57
  4. Faruk Taş · 7 shared papers, 2013–2018 · strength 0.41
  5. Tevhide Bilgen Özcan · 1 shared paper, 2025 · strength 0.27
  6. Ceren Canbey Göret · 1 shared paper, 2025 · strength 0.27
  7. Fikret Ezbercı · 1 shared paper, 2025 · strength 0.27
  8. CigdemUsul Afsar · 1 shared paper, 2020 · strength 0.16
  9. Derya Duranyıldız · 3 shared papers, 2013–2014 · strength 0.13
  10. Nuri Faruk Aykan · 1 shared paper, 2016 · strength 0.06
  11. Kayhan Ertürk · 1 shared paper, 2016 · strength 0.06
  12. İbrahim Yıldız · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.